Abstract 594P
Background
MET alteration, as promising rare target, plays the key role in the development of NSCLC. However, the treatment pattern and efficacy for Chinese NSCLC patients (pts) with MET alteration in real-world setting is limited. Here, we report the treatment pattern and clinical outcome in Chinese NSCLC pts with MET alteration.
Methods
We performed a retrospective, multicenter study in NSCLC pts with MET alteration between Jul. 2021 and Sep. 2022 in China. Patient characteristics, gene profile, and treatment pattern were collected. The objective response rate (ORR) and time to treatment failure (TTF) were analyzed.
Results
202 NSCLC pts with MET alteration were collected. 117 MET exon 14 skipping mutation (MET ex14m) and MET amplification (amp) (MET NGS GCN≥3.5) pts with subsequent efficacy assessment and follow-up data were included for analysis. The ORR of pts with MET ex14m received 1L savolitinib (savo mono), other MET inhibitor (METi) and chemotherapy (chemo)-based regimen were 56.3%, 16.7%, 36.3%, respectively. The ORR of pts with de novo MET amp received savo, other METi, and chemo-based regimen as 1st-line therapy were 66.7%, 0, 20%, respectively. The ORR of post EGFR/ALK-TKI resistance pts with MET amp (resistant MET amp) received savo mono, savo plus osimertinib (osi), other METi and chemo-based regimen were 12.5%, 43.8%, 0, 14.2%, respectively. (Table) Median TTF of 1L savo mono in pts with MET ex14m was 12.6months and median TTF of savo plus osi in pts with resistant MET amp was 11.3 months. Savo discontinuation due to adverse events occurred in MET ex14m, de novo MET amp and resistant MET amp pts were 18.7%, 33.3%, and 7%, respectively. The safety profile of savo were similar to previously reported data. Table: 594P
The ORR result in the analysis
| MET ex14m (n=44) | De novo MET amp (n=16) | Resistant MET amp (n=57) | |||||
| n | ORR | n | ORR | n | ORR | ||
| 1L | Savo | 16 | 56.3% | 3 | 66% | NA | |
| Other METi | 6 | 16.7% | 3 | 0% | |||
| Chemo | 22 | 36.3% | 10 | 20% | |||
| 2L+ | Savo | 14 | 42.8% | 2 | 50% | 8 | 12.5% |
| Savo+osi | 2 | 50% | 2 | 50% | 32 | 43.8% | |
| Other METi | 3 | 0 | 0 | NA | 3 | 0 | |
| Chemo | 23 | 26.1% | 14 | 28.5% | 14 | 14.2% |
Conclusions
The real-world analysis results showed the promising clinical benefit of savo in NSCLC pts with MET alterations and the acceptable safety. Follow-up of these pts are still ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract